An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids (Q66400969)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids |
clinical trial |
Statements
An Open-Label Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids (English)
0 references
26 July 2016
0 references
4 May 2017
0 references
20
0 references
18 year
0 references
47 year
0 references